Vaping Δ <sup>9</sup> -tetrahydrocannabinol (Δ <sup>9</sup> -THC) in liquid forms: pharmacokinetics, pharmacodynamics, and regulatory implications
While more potent than smoked cannabis, vaped liquid formulations with Δ<sup>9</sup>-THC may have a similar PK/PD profile through modulation of Δ<sup>9</sup>-THC delivery by consumer use behaviors. Potential health effects of high-potency vaping products with Δ<sup>9</sup>-THC in liquid form need to be carefully studied. Lastly, researchers should continue to think creatively about how this important work can progress, while restrictions on Δ<sup>9</sup>-THC continue to hinder research.
Authors
- Danielle M. Smith (ORCID: https://orcid.org/0000-0002-1637-0992)
- Block Aw
- Maciej Lukasz Goniewicz (ORCID: https://orcid.org/0000-0001-6748-3068)
Institutions
- Roswell Park Comprehensive Cancer Center (US)
Publication Details
- Journal
- Expert Review of Clinical Pharmacology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1080/17512433.2026.2630756
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00